Press Releases

LOS ANGELES--(BUSINESS WIRE)-- The public will get its first look at the Cadillac 2011 CTS Coupe when it goes on display at The Grove Wednesday, December 2. The new CTS Coupe, which is virtually unchanged from the concept car, is a luxury sport coupe that is the centerpiece of the Cadillac brand and intended to appeal to a new generation of car enthusiasts. The CTS Coupe will be available in showrooms in summer 2010.

The car will be delivered Wednesday morning on The Grove Drive, removed from its transport and driven down the main street of the center where it will be on display on a special stage over the fountain from December 2 -7. Media are invited to see the car drive down The Grove's center street, a rare opportunity to see an early production model in action.

A special unveiling program with entertainment will take place at 7:00 p.m. to officially unveil this sleek and technologically advanced vehicle to the public.

About Cadillac

Cadillac has been a leading luxury auto brand since 1902. In recent years, Cadillac has engineered a historic renaissance led by dramatic new designs and global expansion. More information on Cadillac can be found at media.cadillac.com.

WHAT:     PUBLIC UNVEILING OF CADILLAC 2011 CTS COUPE - On display from
          December 2 - 7

          8:00 a.m. - Cadillac 2011 CTS Coupe driven into center of The Grove -
WHEN:     Be the first to show the public this new sports vehicle from a
          leading American automaker

          7:00 p.m. - Official public unveiling with entertainment, center
          stage at The Grove

WHERE:    The Grove

          189 The Grove Drive - Town Square

          Fairfax District in Los Angeles

CONTACT:  Ashley Greer at 310-473-8090; after hours call 760-485-0149.

    Source: The Grove

EDMONTON, ALBERTA--(Marketwire - Dec. 1, 2009) - Brilliant Mining Corp. (TSX VENTURE: BLT) (the "Company" or "Brilliant") is pleased to advise shareholders of record as at May 29, 2009 (the "Shareholders") that the six month escrow period imposed on the ordinary shares in Panoramic Resources Ltd. ("Panoramic") that were issued to Brilliant as part-consideration for the acquisition by Panoramic of Brilliant's interest in the Lanfranchi Nickel Mine in Western Australia, has elapsed effective November 26, 2009. As such, these shares are now available for transfer in accordance with the Plan of Arrangement involving Brilliant and its shareholders (the "Arrangement").

Subsequent to expiry of the escrow period, Computershare Investor Services Pty Ltd. ("Computershare"), which maintains Panoramic's share register as agent of Panoramic, has advised Brilliant that each eligible Shareholder and Clearing and Depository Services Inc. ("CDS") or Depository Trust & Clearing Corporation ("DTC") participant must submit an original executed transfer form to Computershare in order for the Panoramic shares to be transferred from Brilliant and registered into their name. Shareholders that held their Common Shares in a brokerage account as at the Effective Date are not required to execute such a transfer form as this will be done by the broker on their behalf.

Transfer forms have been prepared by Brilliant with Shareholder registration information as it appears on the Company's share register or as provided by CDS or DTC; the number of shares of Panoramic distributed to the Shareholder under the Arrangement; as well as other pertinent information required to effect the transfer. These forms are being mailed out to each eligible Shareholder and CDS or DTC participant with instructions for execution and submission for processing.

Once Computershare has received and processed the original signed documents, they shall send, by post, to the address appearing on the share transfer form, a notice indicating the assigned Shareholder Reference Number and other pertinent information.

Shareholders should note that Computershare has advised Brilliant that it will be unable to provide Brilliant with any information concerning the holdings of the transferees once the transfers have been completed; as such Brilliant will be unable to provide Shareholder Reference Numbers or any other information concerning shareholdings in Panoramic once the transfer has been complete.

Background

As previously disclosed in news releases and a letter from Olympia Trust Company to shareholders dated October 8, 2009, under the Arrangement Brilliant distributed an aggregate of 12,000,000 ordinary shares of Panoramic to holders of Class "A" common shares of Brilliant ("Common Shares") on the basis of 0.1639042 Panoramic shares for each pre-consolidated Common Share held at the close of trading on Friday, May 29, 2009 (the "Effective Date"). Shareholders became beneficial owners of the Panoramic shares as at May 29, 2009, however legal title to the Panoramic shares remained in the name of Brilliant due to the escrow requirement, which has now expired.

Since the Effective Date, the Shareholders have realized a dividend from Panoramic of AU$0.02 per share of Panoramic, which was distributed by the Company's transfer agent on October 8, 2009 to the Shareholders. Information about the plans and performance of Panoramic can be found at their website at www.panoramicresources.com.

About Brilliant Mining Corp.

Brilliant Mining Corp. is a two-time TSX-Venture Top 50 award winning resource company in search of undervalued resource opportunities. Brilliant's internationally experienced technical team and Board of Directors aim to leverage their broad range of expertise to acquire and develop high quality, advanced stage mineral projects.

On behalf of the Board of Directors

John Williamson, P. Geol., CEO, President & Director

Brilliant Mining Corp.

Brilliant Mining Corp. is a member of the Discovery Group of Companies, for more information on the group visit www.discoveryexp.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

FOR FURTHER INFORMATION PLEASE CONTACT:
        Brilliant Mining Corp.
        Derek Iwanaka
        Manager, Investor Relations
        Toll Free: 1-888-331-2269 or 604-646-4524
        info@brilliantmining.com
        www.brilliantmining.com

Source: Brilliant Mining Corp.

BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)-- The Jones Company, LLC of St. Louis, Missouri, a wholly owned subsidiary of Pulte Homes, Inc. (NYSE: PHM), filed suit against Laborers' International Union of North America (LiUNA) today alleging that LiUNA and its agents violated federal and state law when it barged into a private employee meeting held by Jones Company and orchestrated an attack against employees attending the meeting. The lawsuit alleges that LiUNA's conduct at the meeting included assaulting employees, destruction of property and other unlawful activities. In the lawsuit, The Jones Company also alleges that LiUNA's conduct was for an illegal purpose under federal labor law and also violated state law.

To read the entire suit as filed today in the Eastern District of Missouri U.S. District Court, please click here.

    Source: Pulte Homes, Inc.

- First Subcutaneous Treatment Approved for HAE -

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dyax Corp. (NASDAQ: DYAX) announced today that the U.S. Food and Drug Administration (FDA) has granted approval for KALBITOR(R) (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older.

HAE is a rare, genetic disorder characterized by severe, debilitating and often painful swelling, which can occur in the abdomen, face, hands, feet and airway. KALBITOR, a potent, selective and reversible plasma kallikrein inhibitor discovered and developed by Dyax, is the first subcutaneous HAE treatment approved in the U.S.

As part of product approval, Dyax has, together with the FDA, established a Risk Evaluation and Mitigation Strategy (REMS) program to communicate the risk of anaphylaxis and the importance of distinguishing between a hypersensitivity reaction and HAE attack symptoms.

"The approval of KALBITOR represents an important milestone in our ongoing commitment to the HAE community," said Gustav A. Christensen, President and Chief Executive Officer of Dyax. "Furthermore, bringing KALBITOR to market validates our mission to discover, develop, and commercialize innovative biopharmaceuticals for unmet medical needs."

"By specifically affecting a key mediator of the inflammation, pain and edema that are characteristic of HAE attacks, KALBITOR may be advantageous in offering physicians a targeted approach for treating acute attacks," said professor Jonathan Bernstein, MD, department of internal medicine, division of immunology/allergy, at the University of Cincinnati College of Medicine. "Additionally, the subcutaneous route of administration and efficacy in treating acute attacks in patients 16 years of age and older, regardless of anatomic location, make KALBITOR an important treatment option."

HAE attacks, which occur on average more than 20 times yearly, are unpredictable and range in progression and severity. An acute episode may occur in one or more anatomical sites, sometimes moving from one site to another. "HAE is a highly unpredictable disease because most attacks occur spontaneously with no identifiable trigger. KALBITOR will provide patients 16 years of age and older and their physicians with an FDA-approved subcutaneous therapy for treating painful and debilitating HAE acute attacks," stated Anthony J. Castaldo, President of the United States Hereditary Angioedema Association (HAEA), a nonprofit patient advocacy organization that represents approximately 6,500 HAE patients in the United States.

KALBITOR HAE Program

The approval of KALBITOR is based on the results of two placebo-controlled Phase 3 clinical studies, known as EDEMA3(R) and EDEMA4(R). Patients having an attack of HAE, at any anatomic location, with at least one moderate or severe symptom, were treated with 30 mg subcutaneous KALBITOR or placebo. Because patients could participate in both trials, a total of 143 unique patients participated. There were 64 patients with abdominal attacks, 55 with peripheral attacks, and 24 with laryngeal attacks. In both trials, the effects of KALBITOR were evaluated using the Mean Symptom Complex Severity (MSCS) score and the Treatment Outcome Score (TOS), two HAE-specific patient-reported outcome endpoints developed by Dyax. These measures evaluated the severity of attack symptoms at all anatomical locations (MSCS score) and response to therapy (TOS). In the EDEMA4 trial at 4 hours, patients treated with KALBITOR demonstrated a greater decrease from baseline in the mean MSCS than placebo (-0.8 vs. -0.4; p = 0.010) and a greater mean TOS (53 vs. 8, p = 0.003). In the EDEMA4 trial at 24 hours, patients treated with KALBITOR also demonstrated a greater decrease from baseline in the mean MSCS than placebo (-1.5 vs. -1.1; p = 0.04) and a greater mean TOS (89 vs. 55, p = 0.03). The results in the EDEMA3 trial were consistent with the EDEMA4 trial results.

Potentially serious hypersensitivity reactions, including anaphylaxis, have occurred in patients treated with KALBITOR. In 255 HAE patients treated with intravenous or subcutaneous KALBITOR in clinical studies, 10 patients (3.9%) experienced anaphylaxis. For the subgroup of 187 patients treated with subcutaneous KALBITOR, 5 patients (2.7%) experienced anaphylaxis. Symptoms associated with these reactions have included chest discomfort, flushing, pharyngeal edema, pruritus, rhinorrhea, sneezing, nasal congestion, throat irritation, urticaria, wheezing, and hypotension. These reactions occurred within the first hour after dosing.

The most common adverse reactions occurring in >=3% of KALBITOR-treated patients and greater than placebo were headache, nausea, diarrhea, pyrexia, injection site reactions, and nasopharyngitis.

KALBITOR AccessSM

In advance of KALBITOR availability and launch, patients and healthcare providers can contact KALBITOR AccessSM to receive information and work with program staff to research patient insurance coverage for KALBITOR. KALBITOR Access is designed as a one-stop point of contact for information about KALBITOR. The program is staffed with dedicated insurance specialists and case managers who will help coordinate patient treatment and access to KALBITOR. Patients and healthcare providers can call 1-888-4KALBITOR (1-888-452-5248) for information and to utilize these services or visit www.KALBITOR.com.

Important KALBITOR Safety Information

Anaphylaxis has been reported after administration of KALBITOR. Because of the risk of anaphylaxis, KALBITOR should only be administered by a healthcare professional with appropriate medical support to manage anaphylaxis and hereditary angioedema. Healthcare professionals should be aware of the similarity of symptoms between hypersensitivity reactions and hereditary angioedema and patients should be monitored closely. KALBITOR should not be administered to patients with known clinical hypersensitivity to KALBITOR.

For more information about KALBITOR, including full prescribing information, visit www.KALBITOR.com.

About HAE

Hereditary angioedema (HAE) is an acute inflammatory condition characterized by episodes of severe, often painful swelling affecting the extremities, the gastrointestinal tract, the genitalia, and in the larynx. HAE is caused by low or dysfunctional levels of C1 esterase inhibitor (C1-INH), a naturally occurring molecule that inhibits plasma kallikrein, a key mediator of inflammation, and other serine proteases in the blood. HAE is estimated to affect 1:10,000 to 1:50,000 individuals.

About Dyax

Dyax is focused on advancing novel biotherapeutics for unmet medical needs, with an emphasis on inflammatory and oncology indications. Dyax utilizes its proprietary drug discovery technology to identify antibody, small protein and peptide compounds for clinical development. Dyax's first product, KALBITOR(R) (ecallantide), is approved in the United States for the treatment of acute attacks of hereditary angioedema in patients 16 years of age and older.

Dyax's lead product candidate is DX-88, a recombinant, small protein that is currently being evaluated for its therapeutic potential in two separate indications. DX-88 is being investigated in two Phase 2 trials for the reduction of blood loss during on-pump cardiothoracic surgery (CTS), which are being conducted by Dyax's partner, Cubist Pharmaceuticals. Additionally, DX-88 is also being investigated in a Phase 1 trial for retinal vein occlusion-induced macular edema by Dyax's partner, Fovea Pharmaceuticals, which has recently entered into an agreement to be acquired by sanofi-aventis.

DX-88 and other compounds in Dyax's pipeline were identified using its patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax leverages this technology broadly with over 70 revenue generating licenses and collaborations for therapeutic discovery, as well as in non-core areas such as affinity separations, diagnostic imaging, and research reagents. Dyax is headquartered in Cambridge, Massachusetts. For online information about Dyax Corp., please visit www.dyax.com.

Dyax Disclaimer

This press release contains forward-looking statements, including statements regarding the prospects for therapeutic benefits and treatment advantages of KALBITOR for HAE and the timing for market launch. Statements that are not historical facts are based on Dyax's current expectations, beliefs, assumptions, estimates, forecasts and projections about the industry and markets in which Dyax competes. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors which may affect the prospects for therapeutic benefits and treatment advantages of KALBITOR for HAE and the timing for market launch include the risks that: others may develop technologies or products superior to KALBITOR or that are on the market before KALBITOR; KALBITOR may not gain market acceptance; Dyax is dependent on the expertise, effort, priorities and contractual obligations of third parties in the manufacture, marketing, sales and distribution of KALBITOR; and other risk factors described or referred to Item 1A, "Risk Factors" in Dyax's most recent Annual Report on Form 10-K and other periodic reports filed with the Securities and Exchange Commission. Dyax cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Dyax undertakes no obligations to update or revise these statements, except as may be required by law.

Dyax, the Dyax logo and KALBITOR are registered trademarks and EDEMA3 and EDEMA4 are registered service marks of Dyax Corp. KALBITOR Access is a service mark of Dyax Corp.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6111571&lang=en

    Source: Dyax Corp.

New Procedure Provides More than Redness Relief for Emotionally Distraught Patients

BEVERLY HILLS, Calif.--(BUSINESS WIRE)-- Recently, world renowned ophthalmologist and vision specialist Dr. Brian S. Boxer Wachler introduced I-Brite(TM) eye whitening, an original and breakthrough procedure created to treat a very common problem: chronic red eyes. For people who suffer from chronic red eyes, the appearance of redness, yellowing or brown spots are the cause of emotional distress, insecurity and low self-esteem. Luckily, I-Brite does more than leave brighter, youthful looking and whiter eyes; the procedure also helps alleviate the emotional anguish often endured by patients their entire lives.

It is estimated that millions of Americans suffer from recurring red eyes, instigating frequent comments from friends and colleagues regarding sleep deprivation and marijuana smoking. For recent I-Brite patient Greg Watterworth, suffering from red eyes influenced even the simplest social interactions.

"It really affects my relationships with people, you can't look people in the eyes... you have a hard time looking in the mirror, you don't go out as often as you would like. It just really affects your self-esteem and self-confidence," Watterworth said.

Chronic red eyes are created when the enlarged and dilated blood vessels on the surface of the eye become irritated. I-Brite(TM) eye whitening alleviates the appearance of tired, red eyes, restoring them to their original bright, white eyes. I-Brite(TM) can also remove yellow or brown pigmented areas that form over the years, also often causing emotional anguish.

"Physical deformities have a profound impact psychologically and socially for an individual," says Dr. Briar Grossman, a Contemporary Psychoanalytic Psychotherapist in Los Angeles with over 22 years of experience. "Specifically, eye disfigurement is difficult in a society that often touts the eyes as the window to the soul. For someone who has gone through life with red, yellow, or 'spotted' eyes, their social experience has often been marked by shunning, teasing, ostracism, and even pity. They have been judged first by their 'different' physical appearance, and, deal with problems of self-esteem, depression, and social and occupational challenges consistently."

I-Brite(TM) eye whitening is characterized as a quick outpatient procedure, often taking less than twenty minutes per eye. Patients are able to return to work the very next day, and whiter, brighter eyes are seen in only two weeks. I-Brite(TM) eye whitening provides a smarter, better solution to a very real and common physical and psychological issue that millions of Americans silently suffer from on a daily basis.

Dr. Brian is currently the only vision specialist performing I-Brite(TM) in the world, helping patients to regain a positive outlook on life.

For more information please visit http://www.boxerwachler.com/whiteeyes or http://www.whitereyes.com.

For media inquiries and/or to arrange an interview, please contact Tyler Barnett at 323.937.1951 or tyler@tylerbarnettpr.com.

    Source: Boxer Wachler Vision Institute